Blinatumomab is a novel bispecific construct that reacts simultaneously to normal CD3⁺ T cells and CD19⁺ ALL cells, creating a tight intercellular connection followed by T cell–mediated cytotoxicity exerted on CD19⁺ blast cells (BiTE mechanism).²  The drug is active at very low concentration and once cell lysis is completed, the effector-blinatumomab complex is released to start over again. With single-agent blinatumomab, a complete and durable molecular remission was observed in approximaely 70% of adult patients with MRD⁺ ALL (see article by Topp et al¹  on page 5185), and a similar activity is also being reported in relapsed ALL. Professional illustration by Paulette Dennis.